Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

LipiDiDiet: Multinutrient drink slows cognitive decline in prodromal Alzheimer's disease

Stephen Padilla
16 Nov 2020
Could there be other ways to prevent development of Alzheimers disease?

A multinutrient intervention has successfully reduced decline in cognition, function, brain atrophy, and disease progression in patients with prodromal Alzheimer’s disease (AD) over 3 years, results of the LipiDiDiet clinical trial have shown. Such benefits tend to increase with early and long-term intervention.

“The 36-month data clearly shows it’s possible to have a significant impact on the early stage of the disease,” said co-author Dr Tobias Hartmann from the Department of Experimental Neurology at Saarland University in Germany. “Importantly, we found the effect to be long-lasting and to improve the longer participants stayed in the trial.”

The LipiDiDiet trial recruited 311 patients with prodromal AD using the International Working Group-1 criteria and randomly assigned participants to active product (125-mL once-a-day drink called Souvenaid) or an isocaloric, same tasting, placebo control drink. Of the randomized patients, 162 completed the study, including 81 with 36-month data eligible for efficacy analysis.

Souvenaid contains a combination of nutrients, which include omega-3 polyunsaturated fatty acids (fish oil), uridine monophosphate, choline, phospholipids, B vitamins, and other nutrients at levels difficult to achieve from normal dietary intake alone.

The outcome measure was change in cognition, measured using the Neuropsychological Test Battery (NTB) 5-item composite. Analyses were by modified intention-to-treat, excluding data obtained after the start of open-label active product or AD medication.

Declines in the NTB 5-item composite (–60 percent; between-group difference, 0.212, 95 percent confidence interval, 0.044–0.380; p=0.014), Clinical Dementia Rating-Sum of Boxes (CDR-SB; –45 percent; p=0.014), memory (–76 percent; p=0.008), and brain atrophy measures were significantly reduced over 3 years. [Alzheimers Dement 2020;doi:10.1002/alz.12172]

Small to medium Cohen’s d effect size (0.25–0.31) was similar to established clinically relevant AD treatment, according to the researchers.

“These results show [that] there is now an evidence-based nutritional option available to doctors to recommend for people with mild cognitive impairment, and furthermore the effects are both considerable in scale and long-lasting,” said Dr Patrick Kamphuis, senior medical affairs director at Nutricia, the developer of the nutritional intervention Souvenaid.

A significant reduction was previously observed in cognitive-functional decline over 24 months as measured by CDR-SB, as well as attenuated hippocampal atrophy. However, cognitive deterioration as measured by NTB 5-item composite in the control group was significantly less than expected. [Lancet Neurol 2017;16:965‐975]

“Now, the cognitive decline over the 36‐month intervention period in the control group was well within the range of the originally anticipated 24‐month decline, and we observed a statistically significant difference on the NTB 5‐item composite favouring the active group,” the researchers noted.

The CDR-SB displays real-life performance and is widely used as a sensitive clinical outcome assessment in prodromal or early AD trials, they added. [J Prev Alzheimers Dis 2015;2:128‐113]

Additionally, the protective effect of the long-term multinutrient intervention on brain structures and the reduction in cognitive and functional decline in prodromal AD indicated the vital role of these nutrients in slowing down the neurodegenerative process in AD.

“The beneficial effect on hippocampal atrophy, with its critical link to memory, might be a basis for the memory benefit reported by several trials with the active intervention in prodromal to mild AD,” the researchers said. [Alzheimers Dement 2010;6:1‐10.e1; J Alzheimers Dis 2012;31:225‐236; Lancet Neurol 2017;16:965‐975]

The LipiDiDiet trial examined the effects of specific multinutrient combination Fortasyn Connect on cognition and related measures in prodromal AD and was conducted by the LipiDiDiet Research Consortium composed of leading researchers in neurology.

“Through research, we’re increasingly learning that early intervention is key, and in the LipiDiDiet study our consortium has been studying the potential long-term effects of certain nutrients on the brain of patients with prodromal AD,” Hartmann said.

Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.